Investing.com Deutsch Market update
Current financial headlines
Sharemaestro Newsreel
Financial news from across the world, newest first. Choose a country or market group, open the source, or continue into the company data.
- Showing
- 1–8
- Headlines
- 8
- Sources here
- 2
- Companies here
- 4
Chronological news
Latest headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
XRAY Q2 Deep Dive: Turnaround Progress Slowed by Market and Segment Headwinds
XRAY Q2 Deep Dive: Turnaround Progress Slowed by Market and Segment Headwinds Dental products company Dentsply Sirona (NASDAQ:XRAY) announced better-than-expected revenue in Q2 CY2026, but sales fell by 4.1% year on year to $898 million. On the other hand, the company's full-year revenue guidance …
Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today
Why Dentsply Sirona (XRAY) Stock Is Trading Lower Today What Happened? Shares of dental products company Dentsply Sirona (NASDAQ:XRAY) fell 6.8% in the afternoon session after the company reported second-quarter 2026 earnings, which featured a beat on profit estimates, was overshadowed by a weak …
Resmed’s stock falls by 7% on soft FY27 outlook
Resmed's shares fell by around 7% after the company forecast a softer than expected fiscal year 2027 (FY27) outlook due to suspended ventilator sales, ongoing macro uncertainty and inflation across electronic components and freight. Releasing its FY26 and Q4 FY26 results concurrently, the California-based …
1% Undervalued? DENTSPLY SIRONA (XRAY) As Earnings Test Its Recovery Story
Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Earnings trigger and recent business updates DENTSPLY SIRONA (XRAY) is in focus after reporting second quarter 2026 earnings on 6 August, alongside reaffirmed full year …
XRAY Stock Falls Despite Q2 Earnings Beat, Wellspect Drives Sales
DENTSPLY SIRONA Inc. XRAY reported second-quarter 2026 adjusted earnings per share (EPS) of 52 cents, down 1.6% year over year on an actual-value basis. The bottom line beat the Zacks Consensus Estimate of 36 cents by 44.4%. GAAP EPS in the quarter was 18 …